Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Annunziata C, et al. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. Int J Cancer 143(5): 1153-1161, 2018. PubMed: 29603728
Baker CC, et al. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61: 962-971, 1987. PubMed: 3029430
Pater MM, Pater A. Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix. Virology 145: 313-318, 1985. PubMed: 2992153
Yee C, et al. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119: 361-366, 1985. PubMed: 2990217
Friedl F, et al. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc. Soc. Exp. Biol. Med. 135: 543-545, 1970. PubMed: 5529598
Scheffner M, et al. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88: 5523-5527, 1991. PubMed: 1648218
Hendricks DT, et al. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 57: 2112-2115, 1997. PubMed: 9187105
Olive PL, Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res. 57: 5528-5533, 1997. PubMed: 9407963
Nucleotide (GenBank) : AF001600 Human papillomavirus type 16 integrated SiHa HPV-16 variant DNA, capsid protein gene, complete cds, and flanking cellular DNA.
Nucleotide (GenBank) : AF001599 Human papillomavirus type 16 integrated SiHa HPV-16 variant, replication protein gene, complete cds, and flanking cellular sequence.
